The transcription factor wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL

Journal of Biological Chemistry

Volumn 287, Issue 39, 2012, Pages 32875-32880

  Bansal, Hima ^a   Seifert, Theresea ^a   Bachier, Carlos ^b   Rao, Manjeet ^a   Tomlinson, Gail ^a   Iyer, Swaminathan Padmanabhan ^c   Bansal, Sanjay ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b TEXAS TRANSPLANT INSTITUTE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOID LEUKEMIA; ANTI-APOPTOTIC PROTEIN; CANCER CELLS; CANCER THERAPY; CELL LINES; DOWN-REGULATION; HEAT SHOCK PROTEIN; HUMAN TUMORS; LEUKEMIA CELLS; MONO-THERAPY; MYELOID LEUKEMIA; OVER-EXPRESSION; PHARMACOLOGICAL INHIBITION; THERAPEUTIC AGENTS; TUMOR NECROSIS FACTORS;

CELL CULTURE; DISEASES; GLYCOPROTEINS; LIGANDS; MACROPHAGES; TRANSCRIPTION FACTORS; TUMORS;

CELL DEATH;

HEAT SHOCK PROTEIN 90; PROTEIN BCL XL; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WILMS TUMOR 1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TRANSACTIVATION;

APOPTOSIS; BCL-X PROTEIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; WT1 PROTEINS;

EID: 84866532841     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.C112.366559     Document Type: Article

References (42)

1. Ashkenazi, A., and Herbst, R. S. (2008) To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 118, 1979-1990 (Pubitemid 351872316)
2. Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M. J., and Okumura, K. (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95, 777-783 (Pubitemid 39545582)
3. Ashkenazi, A. (2008) Directing cancer cells to self-destruct with proapoptotic receptor agonists. Nat. Rev. Drug Discov. 7, 1001-1012
4. Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998) Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 (Pubitemid 28391865)
5. Wang, X. (2001) The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922-2933
6. Abdulghani, J., and El-Deiry, W. S. (2010) TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 14, 1091-1108
7. Zhang, L., and Fang, B. (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12, 228-237 (Pubitemid 40315182)
8. Cheng, J., Hylander, B. L., Baer, M. R., Chen, X., and Repasky, E. A. (2006) Multiple mechanisms underlie resistance of leukemia cells to Apo2 ligand/TRAIL. Mol. Cancer Ther. 5, 1844-1853 (Pubitemid 44323253)
9. MacFarlane, M., Harper, N., Snowden, R. T., Dyer, M. J., Barnett, G. A., Pringle, J. H., and Cohen, G. M. (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukemia. Oncogene 21, 6809-6818 (Pubitemid 35221923)
10. Fakler, M., Loeder, S., Vogler, M., Schneider, K., Jeremias, I., Debatin, K. M., and Fulda, S. (2009) Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 113, 1710-1722
11. Riccioni, R., Pasquini, L., Mariani, G., Saulle, E., Rossini, A., Diverio, D., Pelosi, E., Vitale, A., Chierichini, A., Cedrone, M., Foà, R., Lo Coco, F., Peschle, C., and Testa, U. (2005) TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90, 612-624 (Pubitemid 40780880)
12. Kim, I. K., Jung, Y. K., Noh, D. Y., Song, Y. S., Choi, C. H., Oh, B. H., and Masuda, E. S. (2003) Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2. Br. J. Cancer 88, 910-917
13. Haber, D. A., Buckler, A. J., Glaser, T., Call, K. M., Pelletier, J., Sohn, R. L., Douglass, E. C., and Housman, D. E. (1990) An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms tumor. Cell 61, 1257-1269
14. Yang, L., Han, Y., Suarez Saiz, F., and Minden, M. D. (2007) A tumor suppressor and oncogene: the WT1 story. Leukemia 21, 868-876 (Pubitemid 46672061)
15. Ariyaratana, S., and Loeb, D. M. (2007) The role of the Wilms tumor gene (WT1) in normal and malignant hematopoiesis. Expert Rev. Mol. Med. 9, 1-17 (Pubitemid 46965072)
16. Han, Y., San-Marina, S., Liu, J., and Minden, M. D. (2004) Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene 23, 6933-6941 (Pubitemid 39279994)
17. Simpson, L. A., Burwell, E. A., Thompson, K. A., Shahnaz, S., Chen, A. R., and Loeb, D. M. (2006) The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 107, 4695-4702 (Pubitemid 43882617)
18. Tschan, M. P., Gullberg, U., Shan, D., Torbett, B. E., Fey, M. F., and Tobler, A. (2008) The hDMP1 tumor suppressor is a new WT1 target in myeloid leukemias. Leukemia 22, 1087-1090 (Pubitemid 351689903)
19. Morrison, D. J., English, M. A., and Licht, J. D. (2005) WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res. 65, 8174-8182 (Pubitemid 41330581)
20. Rosenfeld, C., Cheever, M. A., and Gaiger, A. (2003) WT1 in acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 17, 1301-1312 (Pubitemid 36857337)
21. Oka, Y., Tsuboi, A., Kawakami, M., Elisseeva, O. A., Nakajima, H., Udaka, K., Kawase, I., Oji, Y., and Sugiyama, H. (2006) Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr. Med. Chem. 13, 2345-2352 (Pubitemid 44184641)
22. Ogawa, H., Tamaki, H., Ikegame, K., Soma, T., Kawakami, M., Tsuboi, A., Kim, E. H., Hosen, N., Murakami, M., Fujioka, T., Masuda, T., Taniguchi, Y., Nishida, S., Oji, Y., Oka, Y., and Sugiyama, H. (2003) The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101, 1698-1704 (Pubitemid 36237562)
23. Lapillonne, H., Renneville, A., Auvrignon, A., Flamant, C., Blaise, A., Perot, C., Lai, J. L., Ballerini, P., Mazingue, F., Fasola, S., Dehée, A., Bellman, F., Adam, M., Labopin, M., Douay, L., Leverger, G., Preudhomme, C., and Landman-Parker, J. (2006) High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J. Clin. Oncol. 24, 1507-1515 (Pubitemid 46638771)
24. Sugiyama, H. (2002) Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol. Med. 68, 223-237
25. Weisser, M., Kern, W., Rauhut, S., Schoch, C., Hiddemann, W., Haferlach, T., and Schnittger, S. (2005) Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19, 1416-1423 (Pubitemid 41148947)
26. Boublikova, L., Kalinova, M., Ryan, J., Quinn, F., O'Marcaigh, A., Smith, O., Browne, P., Stary, J., McCann, S. R., Trka, J., and Lawler, M. (2006) Wilms tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis, and minimal residual disease monitoring. Leukemia 20, 254-263 (Pubitemid 43148663)
27. Bansal, H., Bansal, S., Rao, M., Foley, K. P., Sang, J., Proia, D. A., Blackman, R. K., Ying, W., Barsoum, J., Baer, M. R., Kelly, K., Swords, R., Tomlinson, G. E., Battiwalla, M., Giles, F. J., Lee, K. P., and Padmanabhan, S. (2010) Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood 116, 4591-4599
28. Elmaagacli, A. H., Koldehoff, M., Peceny, R., Klein-Hitpass, L., Ottinger, H., Beelen, D. W., and Opalka, B. (2005) WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 90, 326-334 (Pubitemid 40388982)
29. Salameh, A., Galvagni, F., Anselmi, F., De Clemente, C., Orlandini, M., and Oliviero, S. (2010) Growth factor stimulation induces cell survival by c-Jun: ATF2-dependent activation of Bcl-xL. J. Biol. Chem. 285, 23096-23104
30. Malhi, H., and Gores, G. J. (2006) TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25, 7333-7335 (Pubitemid 44853423)
31. Hietakangas, V., Poukkula, M., Heiskanen, K. M., Karvinen, J. T., Sistonen, L., and Eriksson, J. E. (2003) Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by down-regulation of c-FLIP. Mol. Cell Biol. 23, 1278-1291 (Pubitemid 36177037)
32. Danial, N. N., and Korsmeyer, S. J. (2004) Cell death: critical control points. Cell 116, 205-219 (Pubitemid 38167313)
33. Trauzold, A., Siegmund, D., Schniewind, B., Sipos, B., Egberts, J., Zorenkov, D., Emme, D., Röder, C., Kalthoff, H., and Wajant, H. (2006) TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25, 7434-7439 (Pubitemid 44853434)
34. Finucane, D. M., Bossy-Wetzel, E., Waterhouse, N. J., Cotter, T. G., and Green, D. R. (1999) Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J. Biol. Chem. 274, 2225-2233
35. Jürgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D., and Reed, J. C. (1998) Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl. Acad. Sci. U.S.A. 95, 4997-5002 (Pubitemid 28208539)
36. Medema, J. P., Scaffidi, C., Krammer, P. H., and Peter, M. E. (1998) Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex. J. Biol. Chem. 273, 3388-3393 (Pubitemid 28109756)
37. Srinivasan, A., Li, F., Wong, A., Kodandapani, L., Smidt, R., Jr., Krebs, J. F., Fritz, L. C., Wu, J. C., and Tomaselli, K. J. (1998) Bcl-xL functions down-stream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells. J. Biol. Chem. 273, 4523-4529 (Pubitemid 28103193)
38. Bai, J., Sui, J., Demirjian, A., Vollmer, C. M., Jr., Marasco, W., and Callery, M. P. (2005) Predominant Bcl-xL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 65, 2344-2352 (Pubitemid 40490145)
39. Song, J. J., An, J. Y., Kwon, Y. T., and Lee, Y. J. (2007) Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance: involvement of Bcl-xL. J. Biol. Chem. 282, 319-328 (Pubitemid 47076650)
40. Shankar, S., and Srivastava, R. K. (2004) Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist. Updat. 7, 139-156 (Pubitemid 38736066)
41. Carter, B. Z., Mak, D. H., Schober, W. D., Dietrich, M. F., Pinilla, C., Vassilev, L. T., Reed, J. C., and Andreeff, M. (2008) Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 111, 3742-3750
42. Hasegawa, H., Yamada, Y., Komiyama, K., Hayashi, M., Ishibashi, M., Yoshida, T., Sakai, T., Koyano, T., Kam, T. S., Murata, K., Sugahara, K., Tsuruda, K., Akamatsu, N., Tsukasaki, K., Masuda, M., Takasu, N., and Kamihira, S. (2006) Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood 107, 679-688 (Pubitemid 43076394)